



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Wenbin MA et al.

Application No./Patent No.: 10/670,472

Filed/Issue Date: September 26, 2003

Entitled: MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF

Ludwig Institute for Cancer Research

(Name of Assignee)

, a

Corporation

Type of Assignee, e.g., corporation, partnership, university, government agency, etc.

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.

The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

[] Additional documents in the chain of title are listed on a supplemental sheet.

- [X] Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 18, 2004
Date

Edward J. McDermott, Esq.

Typed or printed name

Edward A. McDermott, Jr.

Signature

President

Title

ASSIGNMENT

WHEREAS the undersigned [hereinafter (collectively) "ASSIGNOR"] have invented certain new and useful improvements in

"MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF"

for which applications were filed as recited in Schedule A,

WHEREAS LUDWIG INSTITUTE FOR CANCER RESEARCH
 605 Third Avenue
 New York, New York 10158

a New York, not-for-profit corporation (hereinafter "ASSIGNEE") is desirous of acquiring the entire right, title and interest in same:

Now, therefore, in consideration of the sum of one dollar (\$1.00), the receipt whereof is hereby acknowledged, and other good and valuable consideration, the said ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the full and exclusive right to the said invention anywhere in the world and the entire right, title and interest in and to any U.S. patent application and any U.S. patent issuing thereon covering such invention and all corresponding foreign patent applications and patents issuing thereon anywhere in the world.

Said ASSIGNOR hereby authorizes and requests that U.S. Letters Patent issue to said ASSIGNEE, as the assignee of the entire right, title, and interest in and to the same, for the sole use and for the use of its successors, legal representatives, and assigns, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held by said ASSIGNOR had this assignment and sale not been made.

Witness, the hand and seal of the ASSIGNOR on the date(s) indicated.

Date(s)

Signature(s)

WENBIN MA

BENOIT VAN DEN EYNDE

THIERRY BOON FALLEUR

27.04.2004


CATHERINE GERMEAU

PIERRE COULIE

SCHEDULE A

Application No.	Filed
60/413,844	September 27, 2002
60/433,983	December 18, 2002
60/459,263	April 2, 2003
10/670,472	September 26, 2003
PCT/US03/30031	September 26, 2003

FULBRIGHT & JAWORSKI, L.L.P.
801 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 662-0200

ASSIGNMENT

WHEREAS the undersigned [hereinafter (collectively) "ASSIGNOR"] have invented certain new and useful improvements in

"MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF"

for which applications were filed as recited in Schedule A,

WHEREAS LUDWIG INSTITUTE FOR CANCER RESEARCH
605 Third Avenue
New York, New York 10158

a New York, not-for-profit corporation (hereinafter "ASSIGNEE") is desirous of acquiring the entire right, title and interest in same:

Now, therefore, in consideration of the sum of one dollar (\$1.00), the receipt whereof is hereby acknowledged, and other good and valuable consideration, the said ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the full and exclusive right to the said invention anywhere in the world and the entire right, title and interest in and to any U.S. patent application and any U.S. patent issuing thereon covering such invention and all corresponding foreign patent applications and patents issuing thereon anywhere in the world.

Said ASSIGNOR hereby authorizes and requests that U.S. Letters Patent issue to said ASSIGNEE, as the assignee of the entire right, title, and interest in and to the same, for the sole use and for the use of its successors, legal representatives, and assigns, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held by said ASSIGNOR had this assignment and sale not been made.

Witness, the hand and seal of the ASSIGNOR on the date(s) indicated.

Date(s)

Signature(s)

May 19th, 2009

Wenbin Ma
WENBIN MA

BENOIT VAN DEN EYNDE

THIERRY BOON FALLEUR

CATHERINE GERMEAU

PIERRE COULIE

SCHEDULE A

Application No.	Filed
60/413,844	September 27, 2002
60/433,983	December 18, 2002
60/459,263	April 2, 2003
10/670,472	September 26, 2003
PCT/US03/30031	September 26, 2003

FULBRIGHT & JAWORSKI, L.L.P.
801 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 662-0200

ASSIGNMENT

WHEREAS the undersigned [hereinafter (collectively) "ASSIGNOR"] have invented certain new and useful improvements in

"MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF"

for which applications were filed as recited in Schedule A,

WHEREAS LUDWIG INSTITUTE FOR CANCER RESEARCH
605 Third Avenue
New York, New York 10158

a New York, not-for-profit corporation (hereinafter "ASSIGNEE") is desirous of acquiring the entire right, title and interest in same:

Now, therefore, in consideration of the sum of one dollar (\$1.00), the receipt whereof is hereby acknowledged, and other good and valuable consideration, the said ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the full and exclusive right to the said invention anywhere in the world and the entire right, title and interest in and to any U.S. patent application and any U.S. patent issuing thereon covering such invention and all corresponding foreign patent applications and patents issuing thereon anywhere in the world.

Said ASSIGNOR hereby authorizes and requests that U.S. Letters Patent issue to said ASSIGNEE, as the assignee of the entire right, title, and interest in and to the same, for the sole use and for the use of its successors, legal representatives, and assigns, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held by said ASSIGNOR had this assignment and sale not been made.

Witness, the hand and seal of the ASSIGNOR on the date(s) indicated.

Date(s)


Signature(s)

April 8, 2004

WENBIN MA



BENOIT VAN DEN EYNDE

April 20, 2004


THIERRY BOON FALLEUR

April 26, 2004

CATHERINE GERMEAU


PIERRE COULIE

SCHEDULE A

Application No.	Filed
60/413,844	September 27, 2002
60/433,983	December 18, 2002
60/459,263	April 2, 2003
10/670,472	September 26, 2003
PCT/US03/30031	September 26, 2003

FULBRIGHT & JAWORSKI, L.L.P.
801 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 662-0200